Grants and Contracts per year
Personal profile
Research Interests
Target Validation, Lead Discovery, and Lead Optimization for Neglected Diseases
My group focuses on the discovery and preclinical development of new therapeutic leads for neglected diseases. We place a major focus on discovering new therapeutic chemotypes, determining their mechanism of action, and conducting proof-of-concept studies in pharmacokinetic/pharmacodynamic (PK/PD) models of disease. All of the projects are intended to deliver well-validated compounds that have suitable pharmacokinetic and toxicology profiles for detailed in vivo studies. During my independent career, both historically and currently, the projects in my laboratory have been split roughly equally between oncology and protozoal diseases.
Our work spans the entire process from initial identification of new chemical hits through optimization of late leads in animal models and finally to the design and execution of human clinical trials. To date, our work has identified dozens of potential new leads for these diseases with novel mechanisms of action or novel applications. We have contributed to repurposing drugs for clinical trials for ependymoma, infantile ALL, and medulloblastoma; contributed a repurposed clinical candidate for retinoblastoma; and produced a novel clinical candidate, (+)-SJ733, for the treatment of malaria that is currently entering Phase 2 trials (https://clinicaltrials.gov/ct2/show/NCT02867059).
Expertise related to UN Sustainable Development Goals
In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):
Education/Academic qualification
Physiology, Postdoctoral Fellowship, Relationships between cholesterol homeostasis and ras and hedgehog signaling, University of Texas Southwestern Medical Center
Sep 1 1996 → Sep 1 1998
Doctor of Philosophy, The Scripps Research Institute
1996
Bachelor of Arts, Reed College
1990
Fingerprint
- 1 Similar Profiles
Network
-
Rodney Guy Scope: State Matching: Kentucky Network for Innovation & Commercialization (#KYNETIC#) Yr 4
Guy, R. K., Bardo, M. & Dwoskin, L.
1/1/23 → 6/30/23
Project: Research project
-
State Matching: Kentucky Network for Innovation & Commercialization (#KYNETIC#) Yr 3
Dwoskin, L., Arnold, S., Bardo, M., Bondada, S., Fritz, M., Guy, R. K., Hall, E., Kolesar, J., McClure, I., Richards, C., Thorson, J., Ueland, F., Zhang, G., Abdel-Latif, A., Bruntz, R., Cassidy, R., Daugherty, A., Delisle, B., Feola, D., Gabr, M., Gensel, J., Gentry, M., Gordon, S., Hammill, J., Leggas, M., Lima, F., Lu, H., Malluche, H., Rao, M., Sheppard, M., Sun, R., Venditto, V., Zhan, C. & Zheng, F.
7/1/20 → 6/30/23
Project: Research project
-
Preclinical and Clinical Development of SJ733, a Novel PfATP4 Inhibitor for the Treatment of Severe Malaria
Global Health Innovative Technology Fund
3/12/20 → 9/30/24
Project: Research project
-
-
Treating the underserved-developing transformative therapies for choroid plexus carcinoma
4/1/19 → 3/31/25
Project: Research project
-
Combining SJ733, an oral ATP4 inhibitor of Plasmodium falciparum, with the pharmacokinetic enhancer cobicistat: An innovative approach in antimalarial drug development
Gaur, A. H., Panetta, J. C., Smith, A. M., Dallas, R. H., Freeman, B. B., Stewart, T. B., Tang, L., John, E., Branum, K. C., Patel, N. D., Ost, S., Heine, R. N., Richardson, J. L., Hammill, J. T., Bebrevska, L., Gusovsky, F., Maki, N., Yanagi, T., Flynn, P. M., McCarthy, J. S., & 2 others , Jun 2022, In: EBioMedicine. 80, p. 104065Research output: Contribution to journal › Article › peer-review
2 Scopus citations -
Similarly efficacious anti-malarial drugs SJ733 and pyronaridine differ in their ability to remove circulating parasites in mice
SheelaNair, A., Romanczuk, A. S., Aogo, R. A., Haldar, R. N., Lansink, L. I. M., Cromer, D., Salinas, Y. G., Guy, R. K., McCarthy, J. S., Davenport, M. P., Haque, A. & Khoury, D. S., Dec 2022, In: Malaria Journal. 21, 1, 49.Research output: Contribution to journal › Article › peer-review
Open Access2 Scopus citations -
Amino-Substituted 3-Aryl- And 3-Heteroarylquinolines as Potential Antileishmanial Agents
Hammill, J. T., Sviripa, V. M., Kril, L. M., Ortiz, D., Fargo, C. M., Kim, H. S., Chen, Y., Rector, J., Rice, A. L., Domagalska, M. A., Begley, K. L., Liu, C., Rangnekar, V. M., Dujardin, J. C., Watt, D. S., Landfear, S. M. & Guy, R. K., Aug 26 2021, In: Journal of Medicinal Chemistry. 64, 16, p. 12152-12162 11 p.Research output: Contribution to journal › Article › peer-review
Open Access1 Scopus citations -
Antimalarial activity of 2,6-dibenzylidenecyclohexanone derivatives
Eagon, S., Hammill, J. T., Fitzsimmons, K., Sienko, N., Nguyen, B., Law, J., Manjunath, A., Wilkinson, S. P., Thompson, K., Glidden, J. E., Rice, A. L., Falade, M. O., Kimball, J. J., DiBernardo, C. & Guy, R. K., Sep 1 2021, In: Bioorganic and Medicinal Chemistry Letters. 47, 128216.Research output: Contribution to journal › Article › peer-review
Open Access1 Scopus citations -
Identification of Plasmodium falciparum heat shock 90 inhibitors via molecular docking
Everson, N., Bach, J., Hammill, J. T., Falade, M. O., Rice, A. L., Guy, R. K. & Eagon, S., Mar 1 2021, In: Bioorganic and Medicinal Chemistry Letters. 35, 127818.Research output: Contribution to journal › Article › peer-review
Open Access2 Scopus citations
Prizes
-
-
-
Philip S. Portoghese Medicinal Chemistry Lectureship Award
Guy, R. Kip (Recipient), 2022
Prize: Honorary award
Activities
- 1 Editorial work
-
Journal of Medicinal Chemistry (Journal)
R. Kip Guy (Reviewer)
2014 → …Activity: Publication peer-review and editorial work › Editorial work